InterMune Likely First To Market In IPF, But Other Firms Poised To Follow
With an FDA advisory committee recommendation for approval and a May 4 PDUFA date, InterMune holds a significant lead over the rest of the field and should be first to market with a drug to treat idiopathic pulmonary fibrosis
You may also be interested in...
In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.
The start-up is also testing the ability of its monocyte-modulating approach to prevent scarring in glaucoma surgery.
Deal also calls for sales-based milestones, likely pegged to antibody currently in Phase I in idiopathic pulmonary fibrosis and advanced solid tumors.